Close Menu
Home › intellectual property

intellectual property

Jan 23, 2019

Contract Research Startup Galaxy Launches With Initial Focus on Stroke POC Test

Galaxy has licensed IP from Proteome Sciences for the development of a test for the diagnosis and timing of stroke onset to help inform treatment decisions.

Feb 28, 2018

Personal Genome Diagnostics Licenses Tumor Mutation Burden IP From MSKCC

PGDx has the exclusive rights to develop both tissue- and blood-based diagnostics using MSK’s TMB-related intellectual property.

Jan 24, 2018

Premaitha to Appeal UK Patent Infringement Ruling in Case Against Illumina

Premaitha had been sued by Illumina for allegedly infringing on five patents related to noninvasive prenatal testing with its Iona test.

Nov 22, 2017

Orig3n Acquires Interleukin Genetics CLIA Lab, Remaining Assets

Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.

Jun 29, 2017

Enzo Patent Found Invalid in Ongoing IP Lawsuits

Enzo's patent relates to modified nucleotides for diagnostic and therapeutic applications, and is central to separate ongoing lawsuits with diagnostic developers.

Nov 10, 2016

Qiagen to Relaunch GeneReader NGS System in US, Sidestepping IP Dispute With Illumina

Premium

The GeneReader will feature a new sequencing chemistry that Qiagen believes circumnavigates an ongoing IP dispute with Illumina and provides enhanced performance.

Sep 26, 2012

Cepheid to Pay Abaxis $17.25M to Settle Infringement Case

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market Tuesday that it has reached a settlement with Abaxis over litigation the firms had filed against each other a couple of yeasr ago.

Jul 15, 2010

More Trouble for Cepheid MRSA Test as Abaxis Sues for Patent Infringement

Premium

Abaxis claims that Cepheid's PCR-based blood test for methicillin-resistant Staphylococcus aureus infringes its sample prep patents. In response, Cepheid has filed a counterclaim denying the alleged infringement and asking the court to find that Abaxis' patents are invalid.

Jul 13, 2010

Cepheid Files Countersuit against Abaxis in Reagent Patent Dispute

The dispute stems from a licensing agreement in 2005 covering reagent patents held by Abaxis. Cepheid filed a countersuit yesterday, claiming it has not breached the license and asking the court to declare Abaxis' patents invalid.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.